NICE briefing on Caris Molecular Intelligence

NICE briefing on Caris Molecular Intelligence

The National Institute for Health and Care Excellence (NICE) has released a medical technology innovation briefing on Caris Molecular Intelligence (CMI) for guiding cancer treatment.

NICE provides national guidance on improving healthcare in the United Kingdom. The medtech innovation briefing is designed to help the National Healthcare Service and social care commissioners and staff who are considering using new diagnostic technologies.

Currently in the United Kingdom, there is no guidance or standard NHS pathway for locally advanced or metastatic cancer in people who have exhausted all standard lines of therapy but who remain fit enough for further treatments. According to the briefing, the innovative aspects of CMI are that it uses multi-platform molecular profiling to provide a report describing which cancer treatments may have clinical benefit and any relevant, open clinical trials. The profile is based on the molecular characteristics of the patient’s tumour, irrespective of its primary site.

The NICE briefing gathered evidence from a literature search and invited opinions from clinical experts working in the field. The briefing states that most evidence shows that CMI‑guided treatment is associated with better progression-free survival than clinician decisions alone. There is also some evidence that CMI may lead to improved overall survival.

NICE website thumbnail Click here to read the full NICE briefing

 

 

Reference

  1. Medtech innovation briefing MIB120: Caris Molecular Intelligence for guiding cancer treatment [online]. National Institute for Health and Care Excellence. September 2017 (cited 21 September 2017). Available from: [URL link]
Print Friendly, PDF & Email
Created: - Modified: